Basilea Pharmaceutica AG (BSLN.S)
24 Feb 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|52||2016||Chairman of the Board of Directors|
|62||2013||Chief Executive Officer, Member of the Management Committee|
|63||2016||Vice Chairman of the Board of Directors|
|2013||Member of the Management Committee, Chief Financial Officer|
|2013||Member of the Management Committee, Head of Global Human Resources|
- BRIEF-Basilea Pharmaceutica FY 2016 net loss narrows to CHF 51.3 million
- BRIEF-Basilea antifungal Cresemba (isavuconazole) launched in France
- BRIEF-MedCap unit to distribute Basilea's products in Scandinavia
- BRIEF-Basilea announces distribution agreement with Unimedic for Cresemba and Zevtera in Nordic Countries
- BRIEF-Basilea announces partnership for antifungal isavuconazole in Japan